Nexavar Rival Offers Natco Opportunity To Build On Lenalidomide Launch
Viatris Launches First Sorafenib Generic As Teva-Partnered Revlimid Rival Lifts Natco In Q4
Executive Summary
Viatris and Natco have introduced the first US generic version of Nexavar, with the exclusive launch expected to further boost India’s Natco after a healthy financial fourth quarter that was bolstered by revenues from the firm’s recent launch of a Revlimid rival with Teva.
You may also be interested in...
Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.
Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of gAsacol revenues even as Zydus expects volume growth and new launches to help grow its US business
Generics Bulletin Editor’s Picks For Q2 2022
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.